Identifying Methylation Biomarkers for Monitoring Bladder Tumors

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2005 by Copenhagen University Hospital at Herlev.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Copenhagen University Hospital at Herlev
ClinicalTrials.gov Identifier:
NCT00244205
First received: October 24, 2005
Last updated: November 14, 2005
Last verified: November 2005
  Purpose

To investigate the methylation status of 4-6 genes in Urine and matching bladder tissue biopsies, in order to find methylation markers for use in a noninvasive test in monitoring patients with bladder tumors.


Condition Intervention
Bladder Cancer
Procedure: Identifying genes methylated in urine

Study Type: Observational
Study Design: Observational Model: Case Control
Primary Purpose: Screening
Time Perspective: Longitudinal
Official Title: Using PCR Technology (Polymerase Chain Reaction Technology) for Monitoring Patients With Bladder Tumors - Optimizing Genanalyses for Clinical Use.

Resource links provided by NLM:


Further study details as provided by Copenhagen University Hospital at Herlev:

Estimated Enrollment: 120
Study Start Date: November 2005
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with bladder tumors and patients with benign urinary tract conditions with no clinical suspicion of bladder cancer.

Exclusion Criteria:

  • Patients with competing urinary and systemic diseases, pregnant and patients under 18 years of age.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00244205

Contacts
Contact: Reza R Serizawa, MD +45 44884787 ext 82607 rerase01@herlevhosp.kbhamt.dk
Contact: Jørgen H Andersen johvan01@herlevhosp.kbhamt.dk

Locations
Denmark
Copenhagen University Hospital at Herlev Recruiting
Herlev, Copenhagen, Denmark, 2730
Contact: Reza R Serizawa, MD    +45 4488 4787 ext 82607    rerase01@herlevhosp.kbhamt.dk   
Principal Investigator: Reza R Serizawa, MD         
Sponsors and Collaborators
Copenhagen University Hospital at Herlev
Investigators
Principal Investigator: Reza R Serizawa, MD Copenhagen University Hospital at Herlev
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00244205     History of Changes
Other Study ID Numbers: Blæretumor PCR projekt
Study First Received: October 24, 2005
Last Updated: November 14, 2005
Health Authority: Denmark: Danish Medicines Agency

Additional relevant MeSH terms:
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Urinary Bladder Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on July 24, 2014